Aktis Oncology filed for an initial public offering to fund its miniprotein radiopharmaceutical pipeline, including a Lilly‑partnered program and an ongoing US Phase 1b study targeting Nectin‑4. The Boston/Durham developer has attracted capital and strategic partnerships from Eli Lilly, Merck, Pfizer and others and raised roughly $346 million privately before the filing. Aktis said proceeds will support ongoing dose‑escalation and expansion cohorts for Ac‑AKY‑1189 and advance a second asset, along with general corporate uses. The move tests investor appetite for radiopharmaceuticals after a quiet biotech IPO market in 2025.